Leading brokerages have put the spotlight on a small-cap Pharma stock which used to be one of Radhakishan Damani’s favourite stocks. The stock has been described as a “high quality proxy play” and is already in the exalted list of potential 100-bagger stocks
Billionaire stock investors are supposed to have an instinct for sniffing out undervalued stocks with the potential for hefty gains. The fact that the duo of Rakesh Jhunjhunwala & MA Yusuffali has invested large sums in a mid-cap bank implies that mega gains are in the offing for the lucky shareholders of the Bank
Daljeet Kohli is known to be a master of Pharma stocks while Porinju Veliyath is lauded for his expertise in harvesting mega gains from underdog stocks. Both have homed in on a mid-cap Pharma stock but expressed contrary views about its future prospects
A specialty chemical stock described by Sanjoy Bhattacharyya as the “solitary beacon of hope” has caught the attention of ace stock pickers. Motilal Oswal has conducted an expert analysis and certified that re-rating is imminent for the stock and that hefty gains can be harvested from it
A mid-cap bank which was earlier touted as a potential “100-bagger” stock by the cognoscenti and which subsequently fell from grace owing to its “dangerous, unexpected and disappointing shift” in strategy has come back into the reckoning owing to the damage control measures implemented by its management
A mid-cap Pharma stock projected as a potential 100-bagger by the wizards at Motilal Oswal has already filled the coffers of its shareholders with gold. It is claimed that the stock has more potential for gains because it is now at a “game changer” and “strategic inflection point”
Dolly Khanna appears to have overcome her aversion to Pharma stocks. This time, instead of being a lone wolf, she has relied on the collective wisdom of Kishore Bang and Motilal Oswal to home in on a micro-cap Pharma stock with impressive past performance and ambitious future plans
A mid-cap Pharma stock strongly recommended by Sanjoy Bhattacharyya & Saurabh Mukherjea is facing the ignominy of being declared a flop. Luckily, another “100 Bagger” Pharma stock is surging and bringing cheer to investors
A mid-cap Pharma stock has become the favourite of several ace stock pickers because of it’s dominance in the market place, high RoEs, quality management and reasonable valuations. The stock is also proclaimed as a potential 100-bagger stock. Daljeet Kohli claims the stock is a good buy now because it is “ripe for re-rating“
Novice investors like you and me remain in a poverty stricken state throughout our life because of our obsession with the short-term. Motilal Oswal, the founder of MOFSL, has issued the clarion call that we need to think of the long-term if we want to become seriously wealthy
Recent Comments